Century Therapeutics director granted 74k options

Century Therapeutics director Alessandro Riva received a grant of stock options as compensation.

Rhea-AI Filing Summary

Century Therapeutics director Alessandro Riva received a grant of stock options as compensation. The Form 4 shows an award of 74,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $2.24 per share.

The options expire on June 11, 2036 and vest on the earlier of June 11, 2027 or the next annual meeting of stockholders, in each case only if Riva continues in service through the vesting date. Following this grant, he holds 74,000 options directly.

Insider Trade Summary

Grant/Award: 74,000 shares

Grant/Award 1 txn

Insider Riva Alessandro

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	74,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 74,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Options granted: 74,000 options Underlying shares: 74,000 shares Exercise price: $2.24 per share +2 more

5 metrics

Options granted 74,000 options Stock Option (right to buy) grant to director

Underlying shares 74,000 shares Common stock underlying granted options

Exercise price $2.24 per share Conversion or exercise price of options

Expiration date June 11, 2036 Option term end date

Post-grant option holdings 74,000 options Total options held following transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vesting financial

"The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"or (b) the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Century Therapeutics (IPSC) report for Alessandro Riva?

Century Therapeutics reported a compensation-related grant of 74,000 stock options to director Alessandro Riva. Each option allows him to buy one share of common stock at an exercise price of $2.24 per share.

What are the key terms of Alessandro Riva’s 74,000 stock options at Century Therapeutics (IPSC)?

Riva’s 74,000 stock options have an exercise price of $2.24 per share and expire on June 11, 2036. They cover an equal number of common shares, giving him a right, not an obligation, to purchase those shares.

When do Alessandro Riva’s stock options at Century Therapeutics (IPSC) vest?

The options vest on the earlier of June 11, 2027 or the next annual meeting of stockholders. Vesting in either case is conditioned on Riva’s continued service through the applicable vesting date.

Is Alessandro Riva’s Form 4 transaction in Century Therapeutics (IPSC) an open-market buy or a grant?

The Form 4 reports a grant, not an open-market purchase. The transaction code is “A,” described as a grant, award, or other acquisition of 74,000 stock options provided as part of Riva’s compensation package.

How many Century Therapeutics (IPSC) options does Alessandro Riva hold after this Form 4 transaction?

After this reported transaction, Riva holds 74,000 stock options directly. These options relate to 74,000 underlying shares of common stock and are subject to the stated vesting schedule and expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riva Alessandro

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.24	06/11/2026		A		74,000		(1)	06/11/2036	Common Stock	74,000	$0	74,000	D

Explanation of Responses:

1. The option vests on the earlier of (a) June 11, 2027, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Douglas Carr, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)